Tesla
TSLA
MicroStrategy
MSTR
MARA Holdings
MARA
Apple
AAPL
Microsoft
MSFT
US Stock MarketDetailed Quotes
DTIL Precision BioSciences
- 5.4400
- -0.6800-11.11%
Close Dec 13 16:00 ET
- 5.4400
- 0.00000.00%
Post 20:02 ET
41.73MMarket Cap-19.43P/E (TTM)
6.1750High5.3850Low94.67KVolume6.1200Open6.1200Pre Close541.85KTurnover1.52%Turnover RatioLossP/E (Static)7.67MShares19.429952wk High0.64P/B33.96MFloat Cap5.120052wk Low--Dividend TTM6.24MShs Float710.1060Historical High--Div YieldTTM12.91%Amplitude5.1200Historical Low5.7230Avg Price1Lot Size
About Precision BioSciences Company
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
Company Profile
SymbolDTIL
Company NamePrecision BioSciences
Listing DateMar 28, 2019
Issue Price16.00
Founded2006
CEOMr. Michael Amoroso
MarketNASDAQ
Employees109
Fiscal Year Ends12-31
AddressDibrell Building,302 East Pettigrew Street,Suite A-100
CityDurham
ProvinceNorth Carolina
CountryUnited States of America
Zip Code27701
Phone1-919-314-5512
Company Executives
- Name
- Position
- Salary
- Michael Amoroso
- Director, President and Chief Executive Officer
- 2.04M
- Jeff Smith, PhD
- Chief Research Officer
- --
- John Alexander Kelly
- Chief Financial Officer and Principal Accounting Officer
- 1.08M
- Dr. Murray Abran, M.D.
- Senior Vice President and Head, Clinical Development
- --
- Kevin J. Buehler
- Chairman of the Board
- 188.49K
- Dr. Samuel C. Wadsworth, PhD
- Independent Director
- 149.99K
- Shari Lisa Pire, J.D.
- Independent Director
- 158.90K
- Geno J. Germano
- Independent Director
- 169.74K
- Melinda Brown
- Independent Director
- 158.99K
- Dr. Stanley R. Frankel, M.D.
- Independent Director
- 156.24K
- John Fry
- Strategic Clinical Advisor, Hepatitis
- --
- Dario Scimeca
- General Counsel and Secretary
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.